Inozyme Pharma, (id:8179 INZY)
2.81 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 4:18:31 PM)
Exchange closed, opens in 17 hours 11 minutes
4.85 USD (4.85%)
-9.35 USD (-9.35%)
-48.44 USD (-48.44%)
-37.56 USD (-37.56%)
-27.58 USD (-27.58%)
-86.49 USD (-86.49%)
About Inozyme Pharma,
Market Capitalization 172.81M
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
| Headquarters (address) |
321 Summer Street Boston 02210 MA United States |
| Phone | 857 330 4340 |
| Website | https://www.inozyme.com |
| Employees | 59 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | INZY |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 2.61 - 7.80 |
| Market Capitalization | 172.81M |
| P/E trailing | -2.05 |
| P/E forward | -1.66 |
| Price/Book | 2.09 |
| Beta | 1.54 |
| EPS | -1.55 |
| EPS United States (ID:6, base:3402) | 24.22 |